CN110201109A - One kind is for treating dermopathic emulsifiable paste and its preparation process - Google Patents

One kind is for treating dermopathic emulsifiable paste and its preparation process Download PDF

Info

Publication number
CN110201109A
CN110201109A CN201910577186.XA CN201910577186A CN110201109A CN 110201109 A CN110201109 A CN 110201109A CN 201910577186 A CN201910577186 A CN 201910577186A CN 110201109 A CN110201109 A CN 110201109A
Authority
CN
China
Prior art keywords
parts
emulsifiable paste
kuh
raw
seng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910577186.XA
Other languages
Chinese (zh)
Inventor
王思农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gansu University of Chinese Medicine
Original Assignee
Gansu University of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gansu University of Chinese Medicine filed Critical Gansu University of Chinese Medicine
Priority to CN201910577186.XA priority Critical patent/CN110201109A/en
Publication of CN110201109A publication Critical patent/CN110201109A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/904—Stemonaceae (Stemona family), e.g. croomia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention proposes a kind of for treating dermopathic emulsifiable paste and its preparation process.Wherein for treating dermopathic emulsifiable paste, it is composed of the following raw materials in parts by weight, 1-5 parts of kuh-seng; it is 1-5 parts of rhizoma atractylodis, 1-5 parts of Cortex Phellodendri, tuber of stemona 1-5 parts raw; 0.2-1 parts of borneol, 0.1-0.5 parts of muscone, 0.1-0.5 parts of calculus bovis factitius; 0.1-0.5 parts of Pulvis Fellis Suis, 0.5-2 parts of Pityrol, 0.1-0.5 parts of eucalyptus oil; 1-5 parts of zinc oxide; 1-5 parts of azone, 8-12 parts of albolene, 65-75 parts of emulsifiable paste matrix.Emulsifiable paste produced by the present invention can treat all anaphylaxis and autoimmune skin disease, be made of flavour of a drug such as kuh-seng, rhizoma atractylodis, have the benefits of anti-inflammation detumescence, desinsection is antipruritic, for treating for skin disease such as eczema, dermatitis, acne, chronic simple lichen, psoriasis.

Description

One kind is for treating dermopathic emulsifiable paste and its preparation process
Technical field
The invention belongs to technical field of traditional Chinese medicine preparation, and in particular to a kind of to treat dermopathic emulsifiable paste and its preparation process.
Background technique
Skin disease is the general name occurred in skin and skin accessory organ's disease.Skin is the maximum organ of human body, skin The type of disease is not only various, and the disease that a variety of internal organ occur can also have performance on the skin.Cause dermopathic reason very much, Such as skin disease caused by infective agent, such as leprosy, scabies, nosomycosis, bacterial skin infections usually have certain infectiousness, Health is not only influenced, and is raised fear and social discrimination, but with the improvement of people ' s living standards and science and technology Progress, the infectious diseases such as leprosy have been obviously controlled in the whole world.Other cause dermopathic interior external factor, such as mechanical Property, it is physical, chemically, biological, incretion, immunity etc., be increasingly valued by people at present.
However, Western medicine is often used for treating for skin disease, it is not only expensive, however hormone is added in drug, stop It is easy to recur after medicine, it is easy to produce drug dependence and drug resistance, being used for a long time can also generate side effect to human body.Although having at present Some Chinese medicine class products, however the therapeutic effect of current Chinese medicine class product is not obvious.
Summary of the invention
In order to solve the above-mentioned technical problem, the present invention proposes a kind of for treating the drug of dermatitis, is by following skill What art scheme was realized, the raw material including following parts by weight is 1-5 parts of kuh-seng, 1-5 parts of rhizoma atractylodis, 1-5 parts of Cortex Phellodendri, tuber of stemona 1-5 parts raw, 0.2-1 parts of borneol, 0.1-0.5 parts of muscone, 0.1-0.5 parts of calculus bovis factitius, 0.1-0.5 parts of Pulvis Fellis Suis, Pityrol 0.5-2 Part, 0.1-0.5 parts of eucalyptus oil, 1-5 parts of zinc oxide.
Preferably, which includes the raw material of following parts by weight, 3 parts of kuh-seng, 3 parts of rhizoma atractylodis, 3 parts of Cortex Phellodendri, gives birth to hundred 3 parts of portion, 0.5 part of borneol, 0.2 part of muscone, 0.2 part of calculus bovis factitius, 0.2 part of Pulvis Fellis Suis, 1 part of Pityrol, eucalyptus oil 0.3 Part, 3 parts of zinc oxide.
Preferably, the dosage form of the composition is paste.
In addition, the present invention also proposes that one kind for treating dermopathic emulsifiable paste, is composed of the following raw materials in parts by weight, kuh-seng It is 1-5 parts, 1-5 parts of rhizoma atractylodis, 1-5 parts of Cortex Phellodendri, tuber of stemona 1-5 parts raw, 0.2-1 parts of borneol, 0.1-0.5 parts of muscone, calculus bovis factitius 0.1-0.5 parts, 0.1-0.5 parts of Pulvis Fellis Suis, 0.5-2 parts of Pityrol, 0.1-0.5 parts of eucalyptus oil, 1-5 parts of zinc oxide, laurel nitrogen 1-5 parts of ketone, 8-12 parts of albolene, 65-75 parts of emulsifiable paste matrix.
Preferably, which is composed of the following raw materials in parts by weight, and 3 parts of kuh-seng, 3 parts of rhizoma atractylodis, 3 parts of Cortex Phellodendri, the raw tuber of stemona 3 Part, 0.5 part of borneol, 0.2 part of muscone, 0.2 part of calculus bovis factitius, 0.2 part of Pulvis Fellis Suis, 1 part of Pityrol, 0.3 part of eucalyptus oil, 3 parts of zinc oxide, 3 parts of azone, 10 parts of albolene, 70 parts of emulsifiable paste matrix.
In addition, the present invention also proposes a kind of for treating the preparation process of dermopathic emulsifiable paste, include the following steps,
(1) 1-5 parts of kuh-sengs, 1-5 parts of rhizoma atractylodis, 1-5 portions of Cortex Phellodendris, the 1-5 parts of raw tubers of stemona, 0.2-1 parts of borneols, 0.1-0.5 are weighed Part muscone, 0.1-0.5 parts of calculus bovis factitiuses, 0.1-0.5 parts of Pulvis Fellis Suis, 0.5-2 parts of Pityrols, 0.1-0.5 parts of eucalyptus oils, 1-5 parts of zinc oxide, 1-5 parts of azones, 8-12 parts of albolene, 65-75 parts of emulsifiable paste matrixes；
(2) by kuh-seng, rhizoma atractylodis, Cortex Phellodendri, the raw tuber of stemona, borneol, muscone, after calculus bovis factitius and Pulvis Fellis Suis co-grinding Sieving；Then Pityrol, eucalyptus oil, zinc oxide, azone, albolene and emulsifiable paste base is added in the raw material after sieving In matter, it is sufficiently mixed uniform emulsifiable paste.
Preferably, 3 parts of the kuh-seng, 3 parts of rhizoma atractylodis, 3 parts of Cortex Phellodendri, raw 3 parts of the tuber of stemona, 0.5 part of borneol, 0.2 part of muscone, 0.2 part of calculus bovis factitius, 0.2 part of Pulvis Fellis Suis, 1 part of Pityrol, 0.3 part of eucalyptus oil, 3 parts of zinc oxide, 3 parts of azone, Bai Fan 10 parts of intellectual circle, 70 parts of emulsifiable paste matrix.
The present invention compared with the existing technology possessed by advantage are as follows: the present invention is for treating dermopathic emulsifiable paste using emulsifiable paste Percutaneous transdermal enhancer azone is added for matrix, and skin even summation excellent, substantially reduce percutaneous drug absorption when Between, and accelerate drug releasing rate；It is absorbed by topical transdermal administration mode, drug absorption is fast, and medicinal component is through to suffer from Place, local drug concentration is high, the toxic side effects such as no gastrointestinal reaction；Be prepared as ointment dosage form, thus improve anti-inflammation detumescence, The antipruritic curative effect of desinsection, and extend and guarantee the quality；Ointment is easy to carry and uses, and emulsifiable paste can directly be applied at itch, do by patient It is controllable to drug concentration；Skin-friendliness is good when emulsifiable paste uses, the medicine retention time is long, fully ensures that Drug Percutaneous Absorption mistake Journey guarantees curative effect.
Emulsifiable paste produced by the present invention can treat all, anaphylaxis and autoimmune skin disease, by flavour of a drug such as kuh-seng, rhizoma atractylodis Composition, has the benefits of anti-inflammation detumescence, desinsection is antipruritic, for skins such as eczema, dermatitis, acne, chronic simple lichen, psoriasis The treatment of disease.
Wherein kuh-seng is mainly used for eczema, wet sore, pruitus, the treatment of castor.Rhizoma atractylodis are used for damp retention in middle-jiao, gastral cavity Distention and fullness in the abdomen, diarrhea, oedema, tinea pedis impotence is preesed, rheumatic arthralgia, anemofrigid cold, yctalopia, the confused puckery treatment of eyes.Cortex Phellodendri is for damp and hot Dysentery, jaundice and reddish urine, leukorrhagia pruritus vulvae, puckery pain of heat gonorrhea, tinea pedis impotence is preesed, sore swollen toxin, the treatment of eczema wet sore.Raw RADIX STEMONAE can be with It is used as medicine, is used for desinsection, antipruritic, delousing outside；It is for oral administration to have the benefits of moistening lung, cough-relieving, eliminating the phlegm.Borneol has inducing resuscitation of having one's ideas straightened out, heat-clearing dissipates poison The effect of, cure mainly high fever and coma due to pyreticosis, apoplexy coma due to blocking of the respiratory system shies epilepsy, summer-heat and damp blinds clear key, throat deafness, aphtha tooth swells, sore carbuncle infantile malnutrition due to digestive disturbances or intestinalparasites hemorrhoid. Muscone has the effects that resuscitation with aromatics, degrading the channel, swelling and pain relieving, can coronary artery dilator, Antianginal effect and nitric acid Glycerol is approximate.Calculus bovis factitius has the effect of clearing heat and detoxicating, resolving sputum is calmed the frightened, and is usually used in phlegm heat and raves mad, in silence, throat is swollen for coma Bitterly, aphthae, the treatment of the illnesss such as carbuncle swells furunculosis.Pulvis Fellis Suis is dry thirsty for pyreticosis, hot eyes, sore throat, jaundice, and pertussis is roared Asthma, diarrhea, dysentery, constipation, ulcerative carbuncle pyogenic infections.Pityrol has the function of anti-inflammatory, regeneration cutin, and there is eucalyptus oil sterilization to make With.
Specific embodiment
In the present invention, unless otherwise stated, Science and Technology noun used herein has art technology The normally understood meaning of personnel institute.
Embodiment 1, the present embodiment propose a kind of for treating dermopathic pharmaceutical composition: the original including following parts by weight Material, kuh-seng 3g, rhizoma atractylodis 3g, Cortex Phellodendri 3g, raw tuber of stemona 3g, borneol 0.5g, muscone 0.2g, calculus bovis factitius 0.2g, Pulvis Fellis Suis 0.2g, Pityrol 1g, eucalyptus oil 0.3g, zinc oxide 3g.
Embodiment 2, the present embodiment propose a kind of for treating dermopathic emulsifiable paste, are composed of the following raw materials in parts by weight, Kuh-seng 3g, rhizoma atractylodis 3g, Cortex Phellodendri 3g, raw tuber of stemona 3g, borneol 0.5g, muscone 0.2g, calculus bovis factitius 0.2g, Pulvis Fellis Suis 0.2g, Pityrol 1g, eucalyptus oil 0.3g, zinc oxide 3g, azone (oil is molten) 3g, albolene 10g, emulsifiable paste matrix 70g.
The product of the present embodiment is antipruritic with kuh-seng 3g, raw tuber of stemona 3g desinsection；Rhizoma atractylodis 3g, Cortex Phellodendri 3g are with heat-clearing and damp-drying drug, removing toxic substances Treat the benefits of sore assists kuh-seng, raw tuber of stemona enhancing is antipruritic；Borneol 0.5g, muscone 0.2g, calculus bovis factitius 0.2g, Pulvis Fellis Suis 0.2g Anti-inflammation detumescence, clearing heat and detoxicating, the powdered medicine ' Tongluosan ' stasis of blood；Pityrol 1g, eucalyptus oil 0.3g, zinc oxide 3g, azone 3g, albolene 10g, emulsifiable paste matrix 70g can promote the suction of all pharmaceutically active ingredients such as kuh-seng as matrix, percutaneous transdermal enhancer and skin penetrant etc. Receipts and skin even summation excellent, substantially reduce the time of percutaneous drug absorption, and accelerate drug releasing rate, this Drug composition and dosage are the summary of professor's Wang Sinong many years medication experience, and prescription and dosage are reasonable, and drug is mutually coordinated, auxiliary It helps, all medicines share, plays anti-inflammation detumescence altogether, the benefits of desinsection is antipruritic, all anaphylaxis and autoimmune skin disease can be treated, by hardship The flavour of a drug such as ginseng, rhizoma atractylodis composition, has the benefits of anti-inflammation detumescence, desinsection is antipruritic, is used for eczema, dermatitis, acne, chronic simple tongue fur The treating for skin disease such as tinea, psoriasis.
The preparation process of the emulsifiable paste is as follows:
1. weighing above-mentioned raw materials；
2. by kuh-seng, rhizoma atractylodis, Cortex Phellodendri, the raw tuber of stemona, borneol, muscone, after calculus bovis factitius and Pulvis Fellis Suis co-grinding Sieve with 100 mesh sieve to obtain feed particulate material；Then Pityrol, eucalyptus oil, zinc oxide, laurel nitrogen is added in the raw material after above-mentioned sieving In ketone, albolene and emulsifiable paste matrix, it is sufficiently mixed uniform that emulsifiable paste is buffered using interior packaging material encapsulating, outer packaging material packaging, It examines, storage.
3 verification test of embodiment
Trial drug is the drug of embodiment 2, it may be assumed that kuh-seng 3g, rhizoma atractylodis 3g, Cortex Phellodendri 3g, raw tuber of stemona 3g, borneol 0.5g, people Work Moschus 0.2, calculus bovis factitius 0.2g, Pulvis Fellis Suis 0.2g, Pityrol 1g, eucalyptus oil 0.3g, zinc oxide 3g, azone (oil It is molten) 3g, albolene 10g, emulsifiable paste matrix 70g.
One, test material
Selection adult healthy Wistar rat 80, half male and half female, SPF grades, weight (220 ± 20) g；By Gansu Chinese medicine Institute's animal experimental center provides, the quality certification number SCXK (sweet) 2009-006, SYXK (sweet) 2009-007.
Ointment for treating dermatitis 1 (2 product of embodiment)；Potassium hydroxide-methanol solution, 0.5% acetic acid, fresh albumen, vaseline, it is sweet Respectful college of traditional Chinese medicine's pharmacological evaluation room provides.100% dimethylbenzene, 52952 chemical plant of Beijing provide, lot number 20090828.Vinegar Sour fluocinolone acetonide ointment, the production of Tianjin pharmaceutcal corporation, Ltd, the quasi- H53020378 of lot number traditional Chinese medicines.Sartorius assay balance, Germany Sai Duolisi company Beijing is providing respectively.T6 ultraviolet-visible spectrophotometer, Beijing Puxi General Instrument Co., Ltd It provides.
Two, test method
Rat is randomly divided into 4 groups, respectively blank group, model group, drug control group, experimental group, every group 20.
Modeling: for Wistar rat in tested preceding 24 hours backs two sides unhairing, unhairing range is about 4cm2, first sterilize unhairing Skin uses Sandpapering feather plucking skin afterwards, until it is degree that micro- oozing of blood, which occurs, in skin.Blank group unhairing is polished without sand paper.
The measurement of surface of a wound area healing rate: 0.1g/cm is pressed2The surface of a wound embrocates ointment for treating dermatitis 1 immediately behind mouse back, experimental group modeling Number, drug control group embrocates fluocinonide ointment group, and physiological saline is wiped outside model group；3 groups timing dressing 1 time daily, even Continuous administration 3w.Blank group does not give any processing, normal to raise.
Wound healing rate is calculated by calculating the content of serum epidermal growth factor.Heart extracting blood is centrifuged, takes Supernatant is placed in -80 DEG C of environment preservations, and then cervical dislocation is put to death.Using table in Enzyme-linked Immunosorbent Assay (ELISA) method detection serum Skin growth factor (EGF).
PGE2The measurement of content: after the completion of Skin sensitization test, ointment for treating dermatitis 1, drug comparison medicine are applied directly to unhaired hide It on skin and damaged skin, is first fixed with gauze, then with appropriately sized rubber gloves, entire back and abdomen is encased.After 3w, With PGE in Elisa method detection each group rat blood serum2Content.Model group and blank group do not smear any drug.
Three, test result: the 3rd after modeling, 7,14,21d, the surface of a wound area of 4 groups of rats is reduced；In same a period of time Between point, experimental group, drug control group Wound healing rate obviously higher than model group, have statistical significance (P < 0.01)；It is real Group is tested compared with the Wound healing rate of drug control group, it is not statistically significant (P > 0.05).
The 3rd after modeling, when 7,14,21d, each group PGE2Content is risen.Experimental group and model group PGE2Comparision contents Have notable difference (P < 0.01), drug control group and model group PGE2Comparision contents have notable difference (P < 0.01), illustrate to test Group, drug control group PGE2Content is apparently higher than model group.Experimental group and drug control group difference it is statistically significant (P < 0.05), illustrate experimental group and drug control group PGE2Content has different.It can be concluded that, product of the present invention is to inflammation above Organize PGE2The raising of content has certain facilitation.(as shown in table 1)
1 ointment for treating dermatitis of table 1 is to PGE in rat blood serum2Content influence
Note: compared with model group, * * P < 0.01；Compared with fluocinonide ointment group,△P < 0.05
Clinical case
Case 1:
Mr. Wang, male, 45 years old, first visit on July 3 in 2018.
There is millet appearance bubble, erosion with violent pruritis, through seeking medical advice without obvious inducement both hands palm before patient's half a year Little in private clinic's curative effect, the present seeks medical advice in my section, our hospital, and existing itch is obvious, the dry chap chap of skin histology with crust, It does not close up long, is diagnosed as " wet sore disease " and is practiced 2 product of example (ointment for treating dermatitis 1) external application then once in the morning and once at night advising patient one week Further consultation afterwards.
Two examine: July 10.Patient skin tissue itch is not very, more wet, and patient is advised to continue external application ointment for treating dermatitis No. 1 one It is discontinued after week.
Three examine: July 17.Patient skin tissue Non Apparent Abnormality.
Case 2:
Cui, female, 25 years old, first visit on October 10 in 2018.
There are red papules without obvious inducement bilateral Face and cheek before patient 2 months, itch is more apparent, is diagnosed as " vulgaris Cuo Sore ", therefore give 1 extra of ointment for treating dermatitis use, once in the morning and once at night, advise patient's further consultation after a week.
Two examine: October 17.Patient's cheek papule partial remission, itch is slight, and patient is advised to continue external application ointment for treating dermatitis 1 Number.
Three examine: October 24.Patient's cheek papule is not very obvious, and patient is advised to continue external application ointment for treating dermatitis 1.
The four methods of diagnosis: October 30.Patient's cheek skin histology Non Apparent Abnormality.
Case 3:
Lee, male, 61 years old, first visit on November 20 in 2018.
Because maculopapule companion desilverization white scales, itch very, are diagnosed as " white Mange " in abdomen after food seafood before patient 5 days, Then give 1 extra of ointment for treating dermatitis use, once in the morning and once at night, advise patient's further consultation after a week.
Two examine: November 27.Patient abdomen skin histology maculopapule partial remission advises patient to continue external application ointment for treating dermatitis 1 Number.
Three examine: December 4.Patient abdomen skin histology maculopapule is unobvious, and patient is advised to continue external application ointment for treating dermatitis 1. Patient skin tissue Non Apparent Abnormality.
The four methods of diagnosis: December 11.Patient abdomen skin histology Non Apparent Abnormality.
The above embodiments are merely illustrative of the technical solutions of the present invention, rather than is limited；Although referring to aforementioned reality Applying example, invention is explained in detail, for those of ordinary skill in the art, still can be to aforementioned implementation Technical solution documented by example is modified or equivalent replacement of some of the technical features；And these are modified or replace It changes, the spirit and scope for claimed technical solution of the invention that it does not separate the essence of the corresponding technical solution.

Claims (7)

1. one kind is for treating dermopathic pharmaceutical composition, which is characterized in that the raw material including following parts by weight, kuh-seng 1-5 Part, it is 1-5 parts of rhizoma atractylodis, 1-5 parts of Cortex Phellodendri, tuber of stemona 1-5 parts raw, 0.2-1 parts of borneol, 0.1-0.5 parts of muscone, calculus bovis factitius 0.1- 0.5 part, 0.1-0.5 parts of Pulvis Fellis Suis, 0.5-2 parts of Pityrol, 0.1-0.5 parts of eucalyptus oil, 1-5 parts of zinc oxide.
2. pharmaceutical composition according to claim 1, which is characterized in that the pharmaceutical composition includes the original of following parts by weight Material, 3 parts of kuh-seng, 3 parts of rhizoma atractylodis, 3 parts of Cortex Phellodendri, raw 3 parts of the tuber of stemona, 0.5 part of borneol, 0.2 part of muscone, 0.2 part of calculus bovis factitius, pig 0.2 part of gallbladder powder, 1 part of Pityrol, 0.3 part of eucalyptus oil, 3 parts of zinc oxide.
3. pharmaceutical composition according to claim 2, which is characterized in that the dosage form of the composition is paste.
4. one kind is for treating dermopathic emulsifiable paste, which is characterized in that it is composed of the following raw materials in parts by weight, it is 1-5 parts of kuh-seng, grey It is 1-5 parts of art, 1-5 parts of Cortex Phellodendri, tuber of stemona 1-5 parts raw, 0.2-1 parts of borneol, 0.1-0.5 parts of muscone, calculus bovis factitius 0.1-0.5 Part, 0.1-0.5 parts of Pulvis Fellis Suis, 0.5-2 parts of Pityrol, 0.1-0.5 parts of eucalyptus oil, 1-5 parts of zinc oxide, 1-5 parts of azone, 8-12 parts of albolene, 65-75 parts of emulsifiable paste matrix.
5. emulsifiable paste according to claim 4, which is characterized in that the emulsifiable paste is composed of the following raw materials in parts by weight, kuh-seng 3 Part, 3 parts of rhizoma atractylodis, 3 parts of Cortex Phellodendri, raw 3 parts of the tuber of stemona, 0.5 part of borneol, 0.2 part of muscone, 0.2 part of calculus bovis factitius, Pulvis Fellis Suis 0.2 Part, 1 part of Pityrol, 0.3 part of eucalyptus oil, 3 parts of zinc oxide, 3 parts of azone, 10 parts of albolene, 70 parts of emulsifiable paste matrix.
6. a kind of for treating the preparation process of dermopathic emulsifiable paste, which is characterized in that include the following steps,
(1) 1-5 parts of kuh-sengs, 1-5 parts of rhizoma atractylodis, 1-5 portions of Cortex Phellodendris, the 1-5 parts of raw tubers of stemona, 0.2-1 parts of borneols, 0.1-0.5 parts of people are weighed Work Moschus, 0.1-0.5 parts of calculus bovis factitiuses, 0.1-0.5 parts of Pulvis Fellis Suis, 0.5-2 parts of Pityrols, 0.1-0.5 parts of eucalyptus oils, 1-5 Part zinc oxide, 1-5 parts of azones, 8-12 parts of albolene, 65-75 parts of emulsifiable paste matrixes；
(2) by kuh-seng, rhizoma atractylodis, Cortex Phellodendri, the raw tuber of stemona, borneol, muscone, mistake after calculus bovis factitius and Pulvis Fellis Suis co-grinding Sieve；Then the raw material after sieving is added to Pityrol, eucalyptus oil, zinc oxide, azone, albolene and emulsifiable paste base Matter is sufficiently mixed uniform emulsifiable paste.
7. preparation process according to claim 6, which is characterized in that 3 parts of the kuh-seng, 3 parts of rhizoma atractylodis, 3 parts of Cortex Phellodendri, raw hundred 3 parts of portion, 0.5 part of borneol, 0.2 part of muscone, 0.2 part of calculus bovis factitius, 0.2 part of Pulvis Fellis Suis, 1 part of Pityrol, eucalyptus oil 0.3 Part, 3 parts of zinc oxide, 3 parts of azone, 10 parts of albolene, 70 parts of emulsifiable paste matrix.
CN201910577186.XA 2019-06-28 2019-06-28 One kind is for treating dermopathic emulsifiable paste and its preparation process Pending CN110201109A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910577186.XA CN110201109A (en) 2019-06-28 2019-06-28 One kind is for treating dermopathic emulsifiable paste and its preparation process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910577186.XA CN110201109A (en) 2019-06-28 2019-06-28 One kind is for treating dermopathic emulsifiable paste and its preparation process

Publications (1)

Publication Number Publication Date
CN110201109A true CN110201109A (en) 2019-09-06

Family

ID=67795379

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910577186.XA Pending CN110201109A (en) 2019-06-28 2019-06-28 One kind is for treating dermopathic emulsifiable paste and its preparation process

Country Status (1)

Country Link
CN (1) CN110201109A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010588A (en) * 2021-11-18 2022-02-08 沈阳信康药物研究有限公司 External temperature-sensitive gel containing black soya bean distillate oil nano zinc oxide pickering emulsion and preparation method and application thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010588A (en) * 2021-11-18 2022-02-08 沈阳信康药物研究有限公司 External temperature-sensitive gel containing black soya bean distillate oil nano zinc oxide pickering emulsion and preparation method and application thereof
CN114010588B (en) * 2021-11-18 2023-11-03 沈阳信康药物研究有限公司 External temperature-sensitive gel containing black soya bean distillate oil nano zinc oxide pickering emulsion and preparation method and application thereof

Similar Documents

Publication Publication Date Title
US20080317879A1 (en) Herb Composition for Asthma Maintenance Therapy and Manufacturing Method Thereof
CN104840816A (en) Composite superfine powder for preventing and treating gout and hyperuricemia and preparation method thereof
CN103877247A (en) Medicine for treating bedsore and preparation method thereof
CN110201109A (en) One kind is for treating dermopathic emulsifiable paste and its preparation process
CN108578478A (en) The Lonicera and Forsythia cream and preparation method thereof massaged for children&#39;s wind-heat cold
Badelbuu et al. Evaluation of the Effect of Aloe Vera Ointment with Chamomile Ointment on Severity of Children’s Diaper Dermatitis: A randomized, double-blind clinical trial
CN109464480A (en) Sore spirit dissipates (cream)
CN110339231B (en) Traditional Chinese medicine composition for treating allergic dermatitis and preparation method thereof
CN104147261B (en) A kind of Chinese medicine preparation for treating rheumatic arthritis
Ghanipour Badelbuu et al. Effects of Aloe vera gel versus chamomile ointment on extent of diaper dermatitis in children: a double-blind randomized controlled trial
CN105853463A (en) Traditional Chinese medicinal preparation for treating carbuncle ulcer and promoting muscle growth as well as preparing method and application thereof
CN110215497A (en) A kind of skin repair cream and its preparation process
CN104027505A (en) Method for preparing traditional Chinese medicine facial mask powder for treating pimple
CN116270839B (en) Traditional Chinese medicine composition for treating rheumatoid arthritis and ankylosing spondylitis as well as preparation method and application thereof
CN108126008A (en) Rosemary cordyceps sinensis ball
CN103656438B (en) Nursing medicine for spine postoperative cuts
CN106728167A (en) A kind of burn and scald external application sterilizing and itch-relieving ointment
CN100356956C (en) Chinese medicine for treating ulcerative stomatitis
CN112006988B (en) Application of medical skin repair spray in preparation of dermatitis treatment medicine
CN100406035C (en) Chinese medicine preparation for treating protrasion of lumbar intervertebral disc
CN102743440A (en) Traditional Chinese medicines for treating femoral head necrosis
CN100455305C (en) Externally applied powder
Majhi et al. MANAGEMENT OF TWAK VAIVARNYA (HYPERPIGMENTATION) THROUGH AYURVED: A CASE STUDY
CN112826831A (en) Traditional Chinese medicine composition for treating skin diseases, preparation method and application
CN105213732A (en) A kind of band bed sore ointment and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190906

RJ01 Rejection of invention patent application after publication